Septerna dosed first participants in Phase 1 trial of SEP-479 oral PTH1R agonist for hypoparathyroidism

Septerna, Inc.

Phase 1 SAD/MAD trial evaluating safety, tolerability, PK/PD in up to 150 healthy volunteers.
SEP-479 is a potent oral small molecule PTH1R agonist for hypoparathyroidism, a lifelong condition.
Data from the trial expected in late 2026 or early 2027.
CEO highlights potential as once-daily oral therapy, differentiating from daily injections or calcium supplements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.